Reduced ALT levels in a dose-dependent manner and slightly reduced cytokeratin-18 fragment levels and AST levels in NASH patients; had hepatoprotective activity in HCV-infected patients. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.